BioMed Technology Funded by Alibaba Hong Kong Entrepreneurs Fund, Gobi and TIMC to Realise Precision and Personalised Gut Microbiome Management for Wellness
Summary
With the outbreak of Covid-19, the demand for personalised nutrition and immune-based products is expected to surge.In view of the auspicious outlook of the self-diagnostic healthcare market in mainland China, the company is stepping up its effort to set up premises including a laboratory in the Shenzhen branch of Hong Kong Science Park. BioMed is committed to promoting knowledge and practice of personalised microbiome health management based on a body of science which has been built over the past decade for the benefit of reducing or even preventing certain conditions or diseases. "Cindy Chow, Executive Director of Alibaba Hong Kong Entrepreneurs Fund said, "The trends of applying research findings on gut microbiome interventions in the healthcare industry have taken shape. "Joseph Lun, Chairman and CEO of The International Medical Co. Ltd. said, "Unlike other companies in the pharmaceutical or health supplement space, BioMed has its own R&D team and laboratories that provide tailor-made solutions and products to consumers. Gobi GBA is the sole general partner (GP) of the Alibaba Hong Kong Entrepreneurs Fund (AEF) as well as the AEF Greater Bay Area Fund (AEF GBA Fund), and has formed strategic partnerships with other renowned financial institutions such as HSBC and Hang Seng Bank.As of 2022, Gobi GBA has invested in over 70 start-ups across the Greater Bay Area and has fostered the growth of 7 unicorns including Airwallex, Amber, Animoca Brands, GoGoX, Prenetics and more.The International Medical Co. Ltd.The International Medical Co. Ltd. (TIMC) is engaged in the marketing and distribution of prescription, OTC drugs and health supplements in Hong Kong, Macau, China, and Singapore.